Transcatheter Pulmonary Artery Banding In Chronic Heart Failure [HFrEF]: Results From the First-in-Human Study

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Ancora Heart; Impluse Dynamics; Medtronic; CareDx; Procyrion; Restore Medical; Valgen Medtech
• Equity/Stock(s)/Options - Transmedics
• Grant Support/Research Contract - Nuwellis